The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Projektinformationen

N-IF

ID Finanzhilfevereinbarung: 785922

DOI

10.3030/785922

Projekt abgeschlossen

EK-Unterschriftsdatum 30 November 2017

Startdatum 1 Dezember 2017

Enddatum 31 Mai 2018

Finanziert unter

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

INFICURE BIO AKTIEBOLAG
Sweden

Periodic Reporting for period 1 - N-IF (The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies)

Berichtszeitraum: 2017-12-01 bis 2018-05-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Fibrosis, or scar tissue within an organ, is a global problem and currently there are no efficient therapies aimed against fibrotic diseases despite their high prevalence among the world population and their huge impact on human health.

Pharma companies are struggling to develop anti-fibrotic drugs due to a lack of good and reliable preclinical models that better resemble human fibrotic disease conditions.

The N-IF mouse, developed by InfiCure Bio, is the first animal model that exhibits the same course of fibrotic disease progression as in humans, is 100% reproducible and spontaneously develops fibrosis. The objectives of the Phase 1 N-IF project were to conduct a feasibility report and prepare for further validation studies of the mouse model in order to establish the pathology of non-alcoholic steatohepatitis (NASH), renal and pulmonary fibrosis enlarging the pipeline models for fibrotic diseases.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

The feasibility study was performed using the Strategic Business Planning Methodology which resulted in an overall business development strategy for the company. The data collected provided a valuable understanding of the current trends and opportunities on the fibrosis market, targeted users, competitors and potential partnerships. The assessment also resulted in a work plan for carrying out validation studies that will provide evidence that usage of the products will lead to a faster and more efficient development of drugs against fibrotic disease. The feasibility study has confirmed that there is a clear business opportunity to exploit on the global fibrosis market and to deliver new experimental models for efficacy testing of anti- fibrotic and anti-inflammatory therapeutics.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

The feasibility study has further confirmed the innovative character of InfiCure Bio’s products. Their unique features such spontaneous development of fibrosis and 100% reproducibility will allow to shorten test protocols by 4-8 weeks, increase robustness of tests and minimize the number of experimental animals needed. Reductions in experiment time and in mice numbers directly translate into a 25 - 50% decrease in the overall costs of preclinical testing of anti-fibrotic drugs. InfiCure Bio will deliver a novel tool for the development of efficient anti-fibrotic therapies that will increase patient survival, improve recovery, decrease the degree of permanent disabilities, improve patient quality life and lower healthcare costs meeting both the clinical and socio-economic needs.

inficure-bio.png